Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

834.04
+7.400.90%
Post-market: 834.040.00000.00%19:58 EDT
Volume:786.92K
Turnover:656.91M
Market Cap:85.87B
PE:20.63
High:847.00
Open:835.74
Low:826.64
Close:826.64
52wk High:847.00
52wk Low:541.00
Shares:102.95M
Float Shares:98.88M
Volume Ratio:1.27
T/O Rate:0.80%
Dividend:3.64
Dividend Rate:0.44%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.71
PE(LYR):20.11

Loading ...

Kymera Rises on Accelerated Trial Timeline for Experimental Eczema Drug

Reuters
·
Jun 25

AbbVie is buying a biotech working on an experimental eczema drug for $10.9 billion

Dow Jones
·
Jun 22

Regeneron Gets FDA, EMA Review of Cemdisiran in Generalized Myasthenia Gravis

Dow Jones
·
Jun 22

Regeneron says FDA accepts cemdisiran gMG filing for priority review

Reuters
·
Jun 22

Regeneron Pharmaceuticals - FDA to Review Cemdisiran Nda Under Priority Review With Target Action Date November 2026

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - European Commission Decision on Cemdisiran Expected in Second Half of 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and Ema for the Treatment of Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS
·
Jun 22

Regeneron Pharmaceuticals - Plans Regulatory Filing for Cemdisiran in Japan in Early 2027

THOMSON REUTERS
·
Jun 22

Cemdisiran Regulatory Submissions Accepted for Review by FDA and EMA for the Treatment of Generalized Myasthenia Gravis (gMG)

GlobeNewswire
·
Jun 22

AbbVie would gain an experimental eczema drug by buying biotech: report

Dow Jones
·
Jun 21

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses On The Day

Dow Jones
·
Jun 18

Regeneron Pharmaceuticals shareholders elect Class II directors at annual meeting

Reuters
·
Jun 18

Regeneron (REGN) Stock Valuation After WHO Ebola Trial Backing And Expanding R&D Collaborations

Simply Wall St.
·
Jun 13

Parabilis Medicines Closes Initial Public Offering

MT Newswires Live
·
Jun 12

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
Jun 11

BUZZ-Drug developer Parabilis Medicines surges in Nasdaq debut

Reuters
·
Jun 11

Parabilis Medicines to Raise $745 Million in IPO, Private Offering

MT Newswires Live
·
Jun 10

Regeneron declares Q2 2026 distribution of R$ 0.05 per unit, payable June 10

Reuters
·
Jun 09

Regeneron Pharmaceuticals Inc. Stock Slips 3.8%, Underperforms Peers

Dow Jones
·
Jun 09

Movement Alert|Regeneron Pharmaceuticals Falls 3.07% in Regular Trading, Phase 3 Clinical Failure and Eylea Biosimilar Threat Weigh on Shares

Market Focus
·
Jun 09